ArticleStem cell research & therapy2025
Human umbilical cord mesenchymal stem cells ameliorate liver fibrosis by inhibiting hepatocyte ferroptosis and macrophage polarization via the miR-455-3p/PLAU axis.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Temporal Transcriptomic Mapping Reveals Angiogenesis and Immune Remodeling During Fat Grafting.Aesthetic plastic surgery · 2026Article
- LINC-EPS Protects Against Neurodegeneration by Driving a PGC-1α-Mediated Anti-Ferroptosis Program in Parkinson's Disease.International journal of biological sciences · 2026Article
- Exploring the impact of DEP on pediatric Crohn's disease using machine learning and molecular docking methods.Frontiers in pediatrics · 2026Article
- Functional characterization of urine-derived stem cells from acute-on-chronic liver failure patients in an immune-mediated acute liver injury model.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPeripheral infusion of human umbilical cord mesenchymal stem cells (hUC-MSCs) may therapeutically treat liver fibrosis. hUC-MSCs can influence liver fibrosis progression and immune microenvironment remodeling via microRNAs (miRNAs).
methodsBioinformatics showed the miR-455-3p/PLAU axis might regulate ferroptosis in liver fibrosis and affect the immune microenvironment. hUC-MSCs were transplanted into CCL4 induced liver-fibrotic male C57BL/6 mice. Liver tissues were stained (Hematoxylin and eosin (H&E), Masson, Sirius Red) to assess fibrosis; Alpha-smooth muscle actin (α-SMA) expression was detected by immunohistochemistry (IHC). Macrophage polarization was measured by immunofluorescence (IF), quantitative real-time polymerase chain reaction (qRT-PCR), and flow cytometry. Dual-luciferase and RNA pull-down assays verified miR-455-3p/PLAU regulation. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL) evaluated liver function. Reactive oxygen species (ROS), glutathione peroxidase 4 (GPX4), iron content, and ferrous iron (Fe
resultsIn fibrotic vs. normal liver tissues, miR-455-3p was down-regulated, PLAU up-regulated, and ferroptosis increased. hUC-MSCs transplantation improves CCL4 induced liver fibrosis by inhibiting ferroptosis of hepatocytes through the miR-455-3p/PLAU axis. It also alleviated macrophage M1 polarization and liver damage.
conclusionhUC-MSCs inhibit hepatocyte ferroptosis via the miR-455-3p/PLAU axis, alleviate macrophage M1 polarization, and slow liver fibrosis. These findings offer insights for future liver fibrosis research and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.